Fibrinogen Concentrates Market Size, Share, Growth, Trends, and Global Industry Analysis:  By Disease Indication (Afibrinogenemia, Dysfibrinogenemia, and Hypofibrinogenemia, Acquired Hypofibrinogenemia, Bleeding Treatment), By Distribution Channel (Hospitals, Ambulatory Surgical Centers, Others) and Region Forecast 2020-2031

Fibrinogen Concentrates Market size was valued at US$ 3.5 billion in 2024 and is expected to reach US$ 5.3 billion by 2031, growing at a significant CAGR of 6.1% from 2025-2031. The fibrinogen concentrate is a pharmaceutical product made from human plasma that contains fibrinogen, a key protein in blood clotting. Fibrinogen is converted into fibrin during the clotting process, helping to form a stable blood clot that stops bleeding. Human fibrinogen concentrate is used to treat people who have congenital or acquired fibrinogen deficiency like hypofibrinogenemia, or acquired fibrinogen deficiency.

The key drivers are the increased prevalence of bleeding disorders such as haemophilia, afibrinogenemia and hypofibrinogenemia, the rise in R&D activity by the market players, and the growth in demand for fibrinogen concentrates in surgical procedures. The emerging trends of the fibrinogen concentrate market are the adoption of advances in product formulations and production techniques, increasing focus on personalised treatment approaches for bleeding disorders, integration of digital health technologies, such as electronic health records and telemedicine is improving the management and monitoring of bleeding disorders, potentially increasing the use of fibrinogen concentrates.

For instance, an increase in complex surgical procedures, including orthopaedic, cardiovascular, and trauma surgeries where fibrinogen concentrate is used to manage bleeding. Moreover, advancements in biotechnology leading to improved product efficacy, rising awareness about the benefits of fibrinogen concentrate therapy, and ongoing clinical research and trials to establish new applications and improve existing formulations drive the human fibrinogen concentrate market over the forecast years.

However, stringent regulatory requirements for product approval, high cost associated with fibrinogen concentrate therapy, limited availability of skilled healthcare professionals for administration, adoption of alternative treatments or therapies for bleeding disorders, and lack of treatment awareness in underdeveloped regions are anticipated to restrain the growth of the market in the forecast timeframe. The fibrinogen concentrate market opportunities are expansion into emerging markets with unmet medical needs, development of novel formulations for improved patient outcomes, and strategic collaborations for market expansion and product development.

Fibrinogen Concentrate Market Key Developments:

• In January 2022, CSL Behring launched its new human fibrinogen concentrate product, Afstyla, in several European markets, aimed at improving the management of bleeding disorders in haemophilia patients.
• In 2024, LFB Group launched an innovative fibrinogen concentrate product featuring a novel purification process aimed at reducing the risk of pathogen transmission and improving overall product safety.